flash chromatography on silica (gradient of n-hexane/EtOAc from 95/5 to 60/40) to give 4 as a white powder (298 mg, 80%). 1 
Ethyl 6-(benzyloxy)-4-(isopropylthio)
quinoline-3-carboxylate 6. 6 was prepared using the previous method from 3 (50 mg, 0.15 mmol), 2-propanethiol (27 µL, 0.30 mmol) and K 2 CO 3 (42 mg, 0.30 mmol) in DMF (2 mL). 6 was isolated after flash chromatography as a yellow oil (35.7 mg, 62.5%). 1 H NMR (400 MHz, CDCl 3 ) δ 8.86 (s, 1H), 8 .07 (d, J = 9.1, 1H), 7.96 (d, J = 2.8, 1H), 7.60 -7.30 (m, 6H), 5.28 (s, 2H), 4.48 (q, J = 7.2, 2H), 3 .32 (hept, J = 6.7, 1H), 1.44 (t, J = 7.2, 3H), 1.14 (d, J = 6.7, 6H). 13 Ethyl 6-(benzyloxy)-4-(ethylthio)quinoline-3-carboxylate 7. 7 was prepared using the previous method from 3 (300 mg, 0.88 mmol), ethanethiol (0.13 mL, 3.52 mmol) and K 2 CO 3 (250 mg, 1.76 mmol) in DMF (3 mL). 7 was isolated after flash chromatography as a yellow oil (290 mg, 90%). 1 H NMR (400 MHz, CDCl 3 ) δ 8.86 (s, 1H), 8.05 (d, J = 9.2, 2H), 7.94 (d, J = 2.8, 1H), 7.61 -7.31 (m, 6H), 5.27 (s, 2H), 4.48 (q, J = 7.2, 2H), 2.83 (q, J = 7.4, 2H), 1 .44 (t, J = 7.2, 3H), 1.13 (t, J = 7.4, 3H). 13 Ethyl 6-(benzyloxy)-4-(methylthio)quinoline-3-carboxylate 8. 8 was prepared using the previous method from 3 (70 mg, 0.20 mmol), sodium methanethiolate (20 mg, 0.60 mmol) and K 2 CO 3 (27.6 mg, 0.20 mmol) in DMF (2 mL).
The reaction mixture was stirred at room temperature for 24 h. 8 was isolated after flash chromatography (100/0 to 70/30 n-hexane/EtOAc) as a yellow oil (8 mg, 11%). 1 Ethyl 6-(benzyloxy)-4-(ethylsulfinyl)quinoline-3-carboxylate 9. A solution of 7 (100 mg, 0.27 mmol) in DCM (3 mL) was cooled to -78°C under an argon atmosphere. mCPBA (75.6 mg, 0.33 mmol, 77% purity) was added portionwise and the mixture was stirred for 4 h at -78 °C. The mixture was extracted with DCM, washed with a solution of saturated sodium bicarbonate and brine, dried over MgSO 4 and concentrated under reduced pressure. The residue was purified by flash chromatography (gradient of hexane/EtOAc from 90/10 to 60/40) to give 9 as a viscous yellow oil (99 mg, 96%). 1 resulting solution was stirred for 20 min at -15 °C and 45 min at room temperature. 7 (50 mg, 0.14 mmol) was added and the mixture was stirred at 110°C for 24 h. Water (2 mL) and sodium hydroxide 10% (m/v) (0.5 mL) were added to the solution and the product was extracted with ethyl acetate. The organic phase was washed with brine, dried and concentrated under reduced pressure. The residue was purified by flash chromatography (gradient from 50/50 nhexane/EtOAc to 100% EtOAc) to give 13 as a white powder (10.5 mg, 21%). 1 
6-(benzyloxy)-N,N-diethyl-4-(ethylsulfanyl)
quinoline-3-carboxamide 14. 14 was prepared according to the previous method using diethylamine (16 µL, 0.15 mmol). The crude product was purified by flash chromatography (gradient from 100% hexane to 100% EtOAc) to give 14 as a off-white powder (15.1 mg, 27%). 1 
6-(benzyloxy)-4-(ethylthio)-N-(2-hydroxyethyl)quinoline-3-carboxamide 18
. 18 was prepared according to the previous method using 2-ethanolamine (9 µL, 0.15 mmol). The crude product was purified by reversed-phase semipreparative HPLC to give 18 as a white powder (4.5 mg, 7%). 1 (q, 2H), 1.14 (t, 3H). 13 3-((tert-butoxycarbonyl) 
Ethyl 6-((

tert-butyl 4-(5-(hydroxymethyl)pyridin-2-yl)piperazine-1-carboxylate 21b. 21a
(200 mg, 0.596 mmol) was dissolved in THF (5 mL) and the solution was cooled to 0 °C. LiAlH 4 (113 mg, 2.98 mmol) was added and the reaction mixture was stirred for 30 min at 0 °C and for 1 h at room temperature. Ice and 10 mL of NaOH 10% (m/v) were added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification over silica (gradient from 100% DCM to 95/10 DCM/MeOH) gave 21b as a white powder (145 mg, 99%). 1 
Ethyl 4-(ethylthio)-6-((6-(piperidin-4-ylamino)pyridin-3-yl)methoxy
ENZYME INHIBITION ASSAY
Final compounds were tested using a previously described fluorogenic 96-well plate assay for PvNMT, 2 PfNMT 3 and HsNMT1/2 4 activity. Data were elaborated using Microsoft Office Excel 2010 and IC 50 values were determined by nonlinear regression fitting using GraFit 7.0 (Erithacus Software Ltd., U.K.). Apparent inhibition constants, K i app ,
were calculated from experimental IC 50 using Cheng-Prussof equation. 5 S10 SUPPLEMENTARY FIGURE S1
Fig. S1 Chemical structure of different lead compounds targeting N-myristoyltransferases from Plasmodium falciparum, 6, 7 Plasmodium vivax, 6 Trypanosoma brucei 8 and Leishmania donovani. 9 S11 SUPPLEMENTARY TABLE S1 
